Phaseline

Targets › TNFRSF25

TNFRSF25 (Tumor necrosis factor receptor superfamily member 25): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Immunology, Other; next expected readout Jul 2028.

Receptor for TNFSF12/APO3L/TWEAK. Interacts directly with the adapter TRADD. Mediates activation of NF-kappa-B and induces apoptosis. May play a role in regulating lymphocyte homeostasis. (UniProt, Q93038)

Open in Phaseline: the race on TNFRSF25, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shattuck LabsSL-325
DR3 blocking antibody
TNFRSF25Phase 2Crohn's Disease; Healthy VolunteersJul 2028

Conditions

Crohn's Disease (1) Healthy Volunteers (1)

Modalities

small molecule (1)

Companies

Shattuck Labs (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.